298. Hereditary pancreatitis
[
79 clinical trials,
116 drugs（DrugBank:
44 drugs),
46 target genes / 121 target pathways ]
Searched query = "Hereditary pancreatitis", "Chronic pancreatitis"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03568630 | July 26, 2018 | 3 December 2018 | Blood Markers of Early Pancreas Cancer | A Longitudinal Cohort Study to Identify Clinical and Blood Markers of Early Pancreas Cancer | Diabetes Mellitus, Type 2;PreDiabetes;Pancreas Cyst;Chronic Pancreatitis;Genetic Predisposition to Disease;Inherited Disease | Diagnostic Test: Other exploratory blood biomarkers;Diagnostic Test: Hemoglobin A1c;Diagnostic Test: Mixed Meal Tolerance Test | University of Nebraska | National Cancer Institute (NCI) | Recruiting | 19 Years | N/A | All | 1250 | Phase 2 | United States |
| 2 | JPRN-UMIN000030735 | 2018/01/15 | 22 July 2019 | Diagnostic accuracy of contrast enhanced endoscopic ultrasonography in pancreatbiliary disease | Diagnostic accuracy of contrast enhanced endoscopic ultrasonography in pancreatbiliary disease - A clinical trial of contrast enhanced endoscopic ultrasonography in the pancreatobiliary disease | Pancreas tumor, Chronic pancreatitis, Autoimmune pancreatitis, Gallblader polyp, Biliary tract tumor | Contrast enhanced endoscopic ultrasonography using perflubutane MRI enhanced CT endoscopic ultrasonography without perflubutane | Department of Endoscopy The Jikei University School of Medicine | Not Recruiting | 20years-old | 100years-old | Male and Female | 786 | Not selected | Japan | |
| 3 | NCT03283566 | October 3, 2017 | 30 September 2019 | Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT | Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing Total Pancreatectomy and Autologous Islet Transplantation: A Clinical, Molecular, and Genomic Study | Chronic Pancreatitis;Insulin Dependent Diabetes | Drug: Hydroxychloroquine;Drug: Placebo | The Cleveland Clinic | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute);Stanford University | Recruiting | 18 Years | 65 Years | All | 10 | Phase 2 | United States |
| 4 | NCT03244683 | August 28, 2017 | 14 October 2019 | A Study of the Efficacy of ONS to Reduce Postoperative Complications Associated With Pancreatic Surgery | A Study of the Efficacy of Oral Nutritional Supplementation to Reduce Postoperative Complications Associated With Pancreatic Surgery | Pancreatic Cancer;Chronic Pancreatitis | Dietary Supplement: Ensure Surgical;Other: Nutrition counseling;Other: Low-intensity exercise therapy | Ohio State University | Abbott Nutrition | Not recruiting | 40 Years | 89 Years | All | 150 | N/A | United States |
| 5 | EUCTR2017-000732-34-DK | 21/06/2017 | 24 July 2017 | Drug Release and Absorption from Controlled Release Formulations in Patients with Gastrointestinal Dysfunctions. | Oral Controlled Release Formulations to Patients with Gastrointestinal Dysfunction – Is the Release of Drug and the Absorption Impaired? - ABOXY | Healthy (pain) and patients (pain). MedDRA version: 20.0 Level: LLT Classification code 10009093 Term: Chronic pancreatitis System Organ Class: 100000016350 MedDRA version: 20.0 Level: LLT Classification code 10012594 Term: Diabetes System Organ Class: 100000019275 MedDRA version: 20.0 Level: LLT Classification code 10048516 Term: Gastrointestinal disorder (NOS) System Organ Class: 100000016398 MedDRA version: 20.0 Level: LLT Classification code 10050554 Term: Gastric bypass NOS System Organ Class: 100000021740 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Oxynorm Product Name: Oxynorm Pharmaceutical Form: Oral solution INN or Proposed INN: Oxycodone CAS Number: 124-90-3 Other descriptive name: OXYCODONE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1- Trade Name: Oxycodonhydrochlorid ”Lannacher”, depot tablets Product Name: Oxycodonhydrochlorid ”Lannacher”, depot tablets Pharmaceutical Form: Modified-release tablet INN or Proposed INN: Oxycodone CAS Number: 124-90-3 Other descriptive name: OXYCODONE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Trade Name: Oxycodone Depot ”Sandoz”, depot tablets Product Name: Oxycodone Depot ”Sandoz”, depot tablets Pharmaceutical Form: Modified-release tablet INN or Proposed INN: Oxycodone CAS Number: 124-90-3 Other descriptive name: OXYCODONE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- | Mech-Sense, Dept. Gastroenterology & Hepatology, Aalborg University Hospital | Authorised | Female: yes Male: yes | Phase 1;Phase 4 | Denmark | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT03481803 | January 27, 2017 | 9 October 2018 | A Phase IIa Study With Escalating Dose of MS1819-SD | A Multicentre Open-label Phase IIa Study With Escalating Dose of MS1819- SD, to Investigate the Efficacy and Safety of a Yarrowia Lipolytica Lipase Preparation for the Compensation of Exocrine Pancreatic Insufficiency Caused by Chronic Pancreatitis and/or Distal Pancreatectomy | Chronic Pancreatitis;Distal Pancreatectomy | Drug: MS1819-SD | AzurRx SAS | Not recruiting | 18 Years | N/A | All | 11 | Phase 2 | Australia;France;New Zealand | |
| 7 | NCT02713997 | December 2016 | 11 November 2019 | Anti-inflammatory Therapy to Improve Outcomes After TPIAT | Anti-inflammatory Therapy to Improve Outcomes in Patients With Chronic Pancreatitis Undergoing Total Pancreatectomy Islet Autotransplantation | Pancreatitis, Chronic; Diabetes; Transplant | Drug: etanercept;Drug: Alpha 1-Antitrypsin | University of Minnesota | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting | 18 Years | 65 Years | All | 45 | Phase 4 | United States |
| 8 | NCT02971475 | November 2016 | 11 June 2018 | ESWL Versus ESWL and Endoscopic Treatment | Extracorporeal Shock Wave Lithotripsy Versus Extracorporeal Shock Wave Lithotripsy Combined With Endoscopic Treatment for Painful Calcified Chronic Pancreatitis | Pancreatitis | Procedure: extracorporeal shock wave lithotripsy;Procedure: endoscopic drainage of the main pancreatic duct;Drug: Analgesics | Changhai Hospital | Recruiting | 18 Years | N/A | All | 62 | N/A | China | |
| 9 | NCT02947087 | October 2016 | 14 January 2019 | Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis | Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival | Chronic Pancreatitis | Drug: Placebo;Drug: Prolastin-C | Medical University of South Carolina | Recruiting | 18 Years | N/A | All | 48 | Phase 1/Phase 2 | United States | |
| 10 | NCT02743364 | September 19, 2016 | 28 October 2019 | Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis | Statin Therapy to Reduce the Risk of Recurrent Pancreatitis | Acute Pancreatitis | Other: Laboratory Biomarker Analysis;Other: Placebo;Other: Quality-of-Life Assessment;Other: Questionnaire Administration;Drug: Simvastatin | National Cancer Institute (NCI) | Not recruiting | 18 Years | N/A | All | 30 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT02965898 | September 2016 | 22 October 2019 | The Effect of Vitamin D Substitution on the Development of Chronic Pancreatitis | The Effect of Vitamin D Substitution on Pancreatic Parenchyma and Development of Fibrosis After First Acute Alcoholic Pancreatitis: A Randomized Prospective Trial | Chronic Pancreatitis | Dietary Supplement: Vitamin D 100ug;Dietary Supplement: Vitamin D 10ug | Tampere University Hospital | Orion Corporation, Orion Pharma | Recruiting | 18 Years | 101 Years | All | 260 | N/A | Finland |
| 12 | NCT02869893 | August 10, 2016 | 30 September 2019 | MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics | Magnetic Resonance Cholangiopancreatography (MRCP): A Reliable, Non Invasive Method for Staging Chronic Pancreatitis From Minimal Change Disease to the Advanced Stages in Pediatrics | Healthy Volunteers | Drug: Secretin | Children's Hospital Medical Center, Cincinnati | ChiRhoClin, Inc.;The National Pancreas Foundation | Not recruiting | 6 Years | 15 Years | All | 57 | N/A | United States |
| 13 | NCT02849704 | July 2016 | 12 February 2018 | Fat Malabsorption in Chronic Pancreatitis | Diagnosing Pancreatic-Based Malabsorption in Patients With Chronic Pancreatitis | Chronic Pancreatitis | Drug: Creon36™ | Children's Hospital of Philadelphia | AbbVie;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);Phoenix Indian Medical Center | Recruiting | 30 Years | 70 Years | All | 48 | Phase 2 | United States |
| 14 | NCT02706236 | April 2016 | 5 March 2018 | Trial of Pancreatic Enzyme Supplements (Pancrelipase) for Treating Pain in Patients With Chronic Pancreatitis | A Single-Center Prospective Randomized Placebo Controlled Trial of Pancreatic Enzyme Supplements (Pancrelipase) for Treating Pain in Patients With Chronic Pancreatitis | Pancreatitis | Drug: Pancrelipase;Drug: placebo | Dartmouth-Hitchcock Medical Center | Not recruiting | 18 Years | N/A | All | 0 | Phase 2 | United States | |
| 15 | EUCTR2015-002570-20-ES | 25/02/2016 | 25 April 2016 | Optimizing treatment of maldigestion in patients with chronic pancreatitis | Open label, randomized, crossover clinical trial to evaluate the efficacy of increasing doses of pancreatic enzymes against inhibition of acid gastric secretion in patients with exocrine pancreatic insufficiency secondary to chronic pancreatitis | Patients diagnosed of chronic pancreatitis with pancreatic exocrine insufficiency under pancreatic enzyme replacement therapy;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Trade Name: Kreon 25000 Product Name: Creon 25000 Product Code: PL 00512/0150 Pharmaceutical Form: Capsule | Department of gastroenterology. University Hospital of Santiago | Authorised | Female: yes Male: yes | Spain | |||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT02693093 | December 2015 | 4 November 2019 | A Dose Ranging Study Evaluating Efficacy and Safety of NI-03 | A Phase 1, Single Dose PK and Safety Study With NI-03 Followed by a Phase 2, Randomized, Double-Blind, Parallel-Group Dose-Ranging Study to Evaluate the Safety and Efficacy of NI-03 When Compared to Placebo in Subjects With Chronic Pancreatitis | Chronic Pancreatitis | Drug: NI-03;Drug: Placebo | Kangen Pharmaceuticals, Inc | Recruiting | 18 Years | 85 Years | All | 128 | Phase 1/Phase 2 | United States | |
| 17 | NCT02538146 | August 2015 | 16 December 2017 | Effect of Acetyl-L-carnitine on Chronic Pancreatitis | Acetyl-L-carnitine as Pain Therapy in Chronic Pancreatitis | Chronic Pancreatitis | Dietary Supplement: acetyl-L-carnitine 1000mg 2X per day for 3 months | Karin High | University of Kentucky | Not recruiting | 20 Years | 90 Years | All | 3 | Early Phase 1 | United States |
| 18 | NCT02577640 | July 2015 | 16 December 2017 | Dietary Soy Isoflavones In Chronic Pancreatitis | Dietary Soy Isoflavones In Chronic Pancreatitis | Chronic Pancreatitis | Dietary Supplement: Soy bread | Ohio State University | Not recruiting | 18 Years | N/A | All | 11 | N/A | United States | |
| 19 | NCT02487225 | May 2015 | 5 March 2018 | Pentoxifylline Treatment in Acute Pancreatitis (AP) | Pentoxifylline Treatment in Acute Pancreatitis: A Double-Blind Placebo - Controlled Randomized Trial | Acute Pancreatitis (AP);Gallstone Pancreatitis;Alcoholic Pancreatitis;Post-ERCP/Post-procedural Pancreatitis;Trauma Acute Pancreatitis;Hypertriglyceridemia Acute Pancreatitis;Idiopathic (Unknown) Acute Pancreatitis;Medication Induced Acute Pancreatitis;Cancer Acute Pancreatitis;Miscellaneous (i.e. Acute on Chronic Pancreatitis) | Drug: Pentoxifylline;Drug: Placebo | Mayo Clinic | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not recruiting | 18 Years | 100 Years | All | 83 | Phase 3 | United States |
| 20 | NCT02567240 | January 2015 | 14 January 2019 | Carbon Monoxide-Saturated Medium for Islet Isolation | A Novel Approach to Harvest Islets for Autologous Islet Transplantation | Chronic Pancreatitis | Other: Carbon monoxide-bubbled mediums | Medical University of South Carolina | Not recruiting | 18 Years | 69 Years | All | 16 | Phase 1/Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT02384018 | December 2014 | 14 January 2019 | Mesenchymal Stem Cell and Islet Co-transplantation | A Phase I Study Evaluating Safety and Tolerability of Autologous Bone Marrow-derived Mesenchymal Stromal Cells in Chronic Pancreatitis Patients Who Undergo Total Pancreatectomy and Islet Autotransplantation. | Chronic Pancreatitis;Diabetes | Biological: autologous mesenchymal stromal cell | Medical University of South Carolina | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not recruiting | 18 Years | 69 Years | All | 24 | Phase 1 | United States |
| 22 | NCT02399800 | December 2014 | 26 February 2018 | Celiac Plexus Block for Chronic Pancreatitis RCT | Prospective Randomized Trial of EUS Guided Celiac Plexus Block for Chronic Pancreatitis | Pancreatitis, Chronic;Pancreatitis | Procedure: Celiac Block with triamcinolone and bupivicaine;Procedure: No Celiac Block;Drug: Intra Plexus Triamcinolone and Bupivicaine Injection | University of Southern California | Not recruiting | 18 Years | N/A | All | 1 | N/A | United States | |
| 23 | NCT01967888 | February 2014 | 28 October 2019 | Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation | A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation | Pancreatectomy for Chronic Pancreatitis | Drug: Reparixin;Drug: Placebo | Dompé Farmaceutici S.p.A | Not recruiting | 18 Years | N/A | All | 104 | Phase 2/Phase 3 | United States;Canada | |
| 24 | EUCTR2013-003357-17-DK | 01/11/2013 | 14 November 2016 | The Ketamine - a novel approach to treating painful chronic pancreatitis. | RESET Trial A randomized, double-blinded, single-centre, parallel-group, placebo-controlled, prospective trial of S-ketamine for pain treatment in chronic pancreatitis (RESET trial) - RESET Trial | Chronic Pancreatitis MedDRA version: 17.1 Level: LLT Classification code 10009093 Term: Chronic pancreatitis System Organ Class: 100000004856 MedDRA version: 17.1 Level: HLT Classification code 10033646 Term: Acute and chronic pancreatitis System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Trade Name: S-Ketamin Product Name: S-ketamin Pharmaceutical Form: Concentrate for solution for infusion Trade Name: Midazolam Product Name: Midazolam Pharmaceutical Form: Solution for injection/infusion Pharmaceutical form of the placebo: Solution for injection/infusion Route of administration of the placebo: Intravenous use | Prof. Asbjørn Mohr Drewes | Not Recruiting | Female: yes Male: yes | 60 | Phase 4 | Denmark | |||
| 25 | JPRN-UMIN000013182 | 2013/10/16 | 2 April 2019 | Efficacy of the pancrelipase for early chronic pancreatitis | early chronic pancreatitis | Pancrelipase no treatment | Fukushima Medical University Aizu Medical Center | Recruiting | Not applicable | Not applicable | Male and Female | 60 | Not selected | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | EUCTR2012-004170-26-IT | 04/12/2012 | 2 June 2014 | Randomized double blinde placebo controlled trial to evaluate the efficacy of N-acetylcystein in patients with chronic pancreatitis and primary sclerosing cholangitis. | Randomized double blinde placebo controlled trial to evaluate the efficacy of N-acetylcystein in patients with chronic pancreatitis and primary sclerosing cholangitis. | Chronic pancreatitis and primary sclerosing cholangitis MedDRA version: 15.0 Level: PT Classification code 10033649 Term: Pancreatitis chronic System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 15.0 Level: PT Classification code 10008609 Term: Cholangitis sclerosing System Organ Class: 10019805 - Hepatobiliary disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Trade Name: FLUIMUCIL*20CPR EFF 600MG Pharmaceutical Form: Effervescent tablet INN or Proposed INN: ACETYLCYSTEINE CAS Number: 616-91-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 600- Pharmaceutical form of the placebo: Effervescent tablet Route of administration of the placebo: Oral use | POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | Not Recruiting | Female: yes Male: yes | 200 | Italy | ||||
| 27 | NCT01551511 | October 2012 | 19 February 2015 | ?9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain | ?9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain: a Randomized, Double-blinded, Placebo-controlled, Parallel Design | Pancreatitis, Chronic;Abdominal Pain;Chronic Pain | Drug: Tetrahydrocannabinol;Drug: Placebo | Radboud University | European Union | Not recruiting | 18 Years | N/A | Both | 29 | Phase 2 | Netherlands |
| 28 | EUCTR2012-000730-19-NL | 23/08/2012 | 28 August 2012 | ?9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain | The analgesic efficacy of ?9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain: a Randomized, Double-blinded, Placebo-controlled, Parallel Design - Delta-Pain II | Chronic pancreatitis with persistant abdominal pain MedDRA version: 14.1 Level: PT Classification code 10033649 Term: Pancreatitis chronic System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Body processes [G] - Digestive System and Oral Physiological Phenomena [G10] | Product Name: Namisol Product Code: A04AD10 Pharmaceutical Form: Tablet INN or Proposed INN: DRONABINOL CAS Number: 03/08/1972 Other descriptive name: Tetrahydro-6,6,9-tri methyl-3-penthyl-6 H-dibenzo[ b,d ]pyran-1-ol Concentration unit: mg milligram(s) Concentration type: range Concentration number: 0.75-5.0 Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Radboud University Nijmegen Medical Centre | Authorised | Female: yes Male: yes | Netherlands | |||||
| 29 | JPRN-UMIN000009547 | 2012/08/01 | 2 April 2019 | Prospectivestudy on the treatment effect of pancrelipase on chronic pancreatitis patient's alubumin concentration | Chronic pancreatitis | 600mg of Pancrelipase (granules or capsels) to be taken three times a day (1800mg /day) after meals for 4 weeks. | Department of Internal Medicine Second Teaching Hospital Fujita Health University School of Medicine | Recruiting | 20years-old | Not applicable | Male and Female | 83 | Not applicable | Japan | ||
| 30 | NCT02458118 | June 2012 | 14 March 2016 | Pancreatic Perfusion Using Secretin and MRI | Study to Assess Pancreatic Blood Flow at Rest and During Stimulation Using Magnetic Resonance Imaging (fMRI) in Patients With Chronic Pancreatitis | Chronic Pancreatitis | Drug: Secretin | University of Nottingham | Recruiting | 18 Years | 80 Years | Both | 15 | Phase 1/Phase 2 | United Kingdom | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | NCT01528540 | April 2012 | 21 September 2015 | Evaluation of Efficacy of Combination of Pregabalin and Antioxidant in Reducing Pain in Chronic Pancreatitis: a Randomized Control Trial | Evaluation of Efficacy of Combination of Pregabalin and Antioxidant in Reducing Pain in Chronic Pancreatitis: a RCT | Chronic Pancreatitis | Drug: Placebo;Drug: Antioxidant plus Pregabalin | Asian Institute of Gastroenterology, India | Not recruiting | 18 Years | 65 Years | Both | 87 | N/A | India | |
| 32 | NCT01318369 | October 2011 | 19 February 2015 | Efficacy Study of ?9-THC to Treat Chronic Abdominal Pain | The Safety, Tolerability, and Analgesic Efficacy of ?9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain | Cannabinoid;Tetrahydrocannabinol;Chronic Pancreatitis;Abdominal Pain | Drug: Namisol;Drug: Diazepam | Radboud University | Not recruiting | 18 Years | N/A | Both | 24 | Phase 2 | Netherlands | |
| 33 | NCT01430234 | October 2011 | 23 March 2015 | Enzyme Suppletion in Exocrine Pancreatic Dysfunction | Enzyme Substitution in Exocrine Pancreatic Insufficiency; Self Administration Against a Fixed Dose Regimen | Chronic Pancreatitis;Exocrine Pancreatic Insufficiency | Drug: Panzytrat 25.000 FIP-E units of Lipase | Foundation for Liver Research | Axcan Pharma | Not recruiting | 18 Years | 90 Years | Both | 10 | Phase 4 | Netherlands |
| 34 | EUCTR2010-020303-69-NL | 19/09/2011 | 19 March 2012 | Enzyme substitution in exocrine pancreatic insufficiency; Self administration against a fixed dose regimen. - SAPES | Enzyme substitution in exocrine pancreatic insufficiency; Self administration against a fixed dose regimen. - SAPES | Exocrine pancreatic insufficiency in patients with chronic pancreatitis MedDRA version: 12.1 Level: LLT Classification code 10041969 Term: Steatorrhoea | Trade Name: Panzytrat Product Name: Panzytrat Product Code: RVG 13760 Pharmaceutical Form: Capsule, soft INN or Proposed INN: pancreatic enzymes CAS Number: 9001621 Other descriptive name: LIPASE Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 25000- | Erasmus MC | Authorised | Female: yes Male: yes | 20 | Netherlands | ||||
| 35 | NCT01318590 | March 2011 | 16 December 2017 | Prospective Study on Endoscopic Ultrasound (EUS) Celiac Bloc Efficacy in Chronic Pancreatitis | Prospective Study on Endoscopic Ultrasound (EUS) Celiac Bloc Efficacy in Chronic Pancreatitis | Pancreatitis, Chronic | Drug: Bupivacaine & Triamcinolone Acetonide;Other: No intervention except EUS procedure | Centre hospitalier de l'Université de Montréal (CHUM) | Centre de Recherche du Centre Hospitalier de l'Université de Montréal;Erasme University Hospital | Recruiting | 18 Years | N/A | All | 100 | Phase 3 | Belgium;Canada |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | NCT01265875 | December 2010 | 19 October 2017 | Secretin Infusion for Pain Due to Chronic Pancreatitis | Secretin Infusion for Pain Due to Chronic Pancreatitis | Chronic Pancreatitis | Drug: Human Secretin | ChiRhoClin, Inc. | Dartmouth-Hitchcock Medical Center | Not recruiting | 18 Years | 70 Years | All | 12 | Phase 1/Phase 2 | United States |
| 37 | NCT01146561 | October 2010 | 19 February 2015 | Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Chronic Pancreatitis | Chronic Pancreatitis | Biological: Tanezumab;Other: Placebo | Pfizer | Not recruiting | 18 Years | N/A | Both | 2 | Phase 2 | United States | |
| 38 | NCT01452217 | September 2010 | 19 February 2015 | Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers | The Use of Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers | Chronic Pancreatitis | Drug: Secretin | University of Nottingham | Not recruiting | 18 Years | 75 Years | Male | 12 | Phase 1 | United Kingdom | |
| 39 | NCT01159119 | August 2010 | 19 February 2015 | A Study of EUR-1066 in Subjects With Chronic Pancreatitis, Exocrine Pancreatic Insufficiency and Chronic Abdominal Pain | Single Center Randomized Single Blind Crossover Group Active Control Study to Evaluate Safety and Efficacy of EUR-1066 a Pancreatic Enzyme Product in Patients With Chronic Pancreatitis Exocrine Pancratic Insufficiency,Chronic Abdominal Pain | Chronic Pancreatitis | Drug: EUR-1066-A;Drug: Zenpep;Drug: EUR-1066-B | Eurand Pharmaceuticals | University of Florida | Not recruiting | 18 Years | N/A | Both | 15 | Phase 1 | United States |
| 40 | NCT01236053 | June 2010 | 16 December 2017 | Cancer in Patients With Gabapentin (GPRD) | Risk of Cancer in Patients Exposed to Gabapentin in the GPRD | Pain, Neuropathic;Epilepsy;Renal Pelvis Cancer;Pancreatic Cancer;Breast Cancer;Nervous System Cancer;Chronic Pancreatitis;Stomach Cancer;Renal Cell Carcinoma;Diabetes;Bladder Cancer;Bone and Joint Cancer;Penis Cancer;Anal Cancer;Cancer;Renal Cancer | Drug: Gabapentin prescriptions | GlaxoSmithKline | Not recruiting | N/A | N/A | All | 2323608 | N/A | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | EUCTR2010-018900-10-FR | 11/05/2010 | 19 March 2012 | Safety and preliminary clinical activity of Yarrowia lipolytica lipase (MS1819) in patients with malabsorption syndrome due to exocrine pancreatic insufficiency resulting from chronic pancreatitis | Safety and preliminary clinical activity of Yarrowia lipolytica lipase (MS1819) in patients with malabsorption syndrome due to exocrine pancreatic insufficiency resulting from chronic pancreatitis | Exocrine pancreatic insufficiency resulting from chronic pancreatitis MedDRA version: 12.1 Level: LLT Classification code 10033628 Term: Pancreatic insufficiency | Product Name: MS1819 Product Code: MS1819 Pharmaceutical Form: Powder for oral solution INN or Proposed INN: Yarrowia lipolytica lipase Current Sponsor code: MS1819 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Powder for oral solution Route of administration of the placebo: Oral use | Laboratoires Mayoly Spindler | Authorised | Female: yes Male: yes | 12 | France | ||||
| 42 | EUCTR2005-000562-38-DE | 20/04/2010 | 10 February 2014 | RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A GASTRO-RESISTANT FILM-COATED PANCREATIN TABLET FOR LIPID DIGESTION AND ABSORPTION IN PATIENTS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CHRONIC PANCREATITIS BY MEANS OF 13C-MIXED TRIGLYCERIDE BREATH TEST - CPI 002 | RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A GASTRO-RESISTANT FILM-COATED PANCREATIN TABLET FOR LIPID DIGESTION AND ABSORPTION IN PATIENTS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CHRONIC PANCREATITIS BY MEANS OF 13C-MIXED TRIGLYCERIDE BREATH TEST - CPI 002 | The purpose of this trial is to evaluate the clinical efficacy and safety of a gastro-resistant film-coated tablet in comparison to placebo in the treatment of pancreatic exocrine insufficiency due to chronic pancreatitis MedDRA version: 7.0 Level: LLT Classification code 10033628 | Trade Name: Mezym F Product Name: Mezym F Product Code: Pancreatin Pharmaceutical Form: Gastro-resistant tablet INN or Proposed INN: Pancreatin Concentration unit: IU international unit(s) Concentration type: not less then Concentration number: 10000 IU lipase- Pharmaceutical form of the placebo: Gastro-resistant tablet Route of administration of the placebo: Oral use | Berlin-Chemie AG | Not Recruiting | Female: yes Male: yes | 20 | Phase 4 | Germany | |||
| 43 | EUCTR2009-016082-29-BE | 10/03/2010 | 14 October 2013 | Role of Lanreotide in the Management of Paraduodenal Pancreatitis - LPP | Role of Lanreotide in the Management of Paraduodenal Pancreatitis - LPP | Paraduodenal pancreatitis MedDRA version: 12.1 Level: LLT Classification code 10009093 Term: Chronic pancreatitis | Trade Name: Somatuline Autogel 90 mg Pharmaceutical Form: Solution for injection CAS Number: 127984741 Other descriptive name: LANREOTIDE ACETATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Erasme hospital | Authorised | Female: yes Male: yes | 60 | Belgium | ||||
| 44 | NCT01138124 | March 2010 | 16 December 2017 | Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD) | Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research Database | Renal Pelvis Cancer;Restless Legs Syndrome;Epilepsy;Neuropathic Pain;Chronic Pancreatitis;Hypertension;Pancreatic Cancer;Diabetes;Renal Cancer;Renal Cell Carcinoma | Drug: Gabapentin prescriptions | GlaxoSmithKline | Not recruiting | N/A | N/A | All | 54202 | N/A | ||
| 45 | JPRN-UMIN000003020 | 2010/01/01 | 2 April 2019 | Establishment of pancreatic exocrine function assaay usin real time 13C breath test. | Chronic pancreatitis, state after pancreatectomy | Expiratory 13CO2 measurement after oral intake of 13C incorporated fatty acids and amino acids in healthy volunteers. Expiratory 13CO2 measurement after oral intake of 13C incorporated fatty acids and amino acids in patients after total pancreatectomy. Expiratory 13CO2 measurement after oral intake of 13C incorporated fatty acids and amino acids in patients after pancreatico duodenectomy. Expiratory 13CO2 measurement after oral intake of 13C incorporated fatty acids and amino acids in patients with chronic pancreatits. | Tohoku University Hospital | Recruiting | 20years-old | 80years-old | Male and Female | 8 | Not applicable | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | NCT01001923 | December 2009 | 19 February 2015 | Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain | Randomized, Double-blind, Placebo-controlled Study of the Effect of a Single Injection of SAR164877 (REGN475) on Reduction of Pain From Chronic Pancreatitis | Abdominal Pain Upper | Drug: REGN475/SAR164877;Drug: Placebo (for REGN475/SAR164877) | Regeneron Pharmaceuticals | Not recruiting | 18 Years | 80 Years | Both | 15 | Phase 2 | United States | |
| 47 | NCT01141998 | December 2009 | 19 February 2015 | Vitamin D Substitution for Patients With Chronic Pancreatitis and Malabsorption | Vitamin D Substitution for Patients With Chronic Pancreatitis and Malabsorption | Chronic Pancreatitis;Malabsorption Syndromes | Drug: Cholecalciferol;Radiation: UV-filtered light.;Radiation: UVB;Drug: Calcium, Dietary | Hvidovre University Hospital | Not recruiting | 18 Years | N/A | Both | 27 | N/A | Denmark | |
| 48 | EUCTR2009-010266-28-NL | 21/07/2009 | 19 March 2012 | Een gerandomiseerde dubbelblinde, placebogecontroleerde, klinische parallelle groep studie van pregabaline in patiënten met chronische pancreatitis - Effect van pregabaline therapie bij patiënten met chronische pancreatitis | Een gerandomiseerde dubbelblinde, placebogecontroleerde, klinische parallelle groep studie van pregabaline in patiënten met chronische pancreatitis - Effect van pregabaline therapie bij patiënten met chronische pancreatitis | chronische pancreatitis MedDRA version: 9.1 Level: LLT Classification code 10009093 Term: Chronic pancreatitis | Trade Name: Lyrica® Pharmaceutical Form: Capsule, hard Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Afdeling heelkunde, Universitair Medisch Centrum Sint Radboud | Authorised | Female: yes Male: yes | 30 | Netherlands | ||||
| 49 | NCT01142128 | February 2009 | 19 October 2017 | Viokase 16, Viokase16 Plus Nexium and Nexium Alone | A Randomized, Single Site, Double Blind, Fixed Dose, Cross Over Study of Viokase 16, Viokase16 Plus Nexium and Nexium Alone in the Reduction of Abdominal Pain in Patients With Chronic Pancreatitis | Chronic Pancreatitis | Drug: Nexium (esomeprazole magnesium);Drug: Placebo to Nexium;Drug: Viokase 16 (pancrelipase) + Nexium;Drug: Viokase 16 + placebo to Nexium | University of Florida | AstraZeneca | Not recruiting | 18 Years | 75 Years | All | 12 | Phase 1 | United States |
| 50 | NCT01259544 | January 2009 | 19 February 2015 | BreathID® Test: A Non-invasive Modality to Detect Pancreatic Exocrine Insufficiency | Chronic Pancreatitis;Healthy Volunteers | Drug: benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala) | Exalenz Bioscience LTD. | Virginia Commonwealth University;Asian Institute of Gastroenterology, Hyderabad, India | Not recruiting | 18 Years | N/A | Both | 33 | Phase 2 | India | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | NCT00782795 | November 2008 | 16 December 2017 | Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality | Phase II Study of Chronic Pancreatitis and the Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality | Chronic Pancreatitis;Insulin Resistance;Normal or Mildly Abnormal Stool Fat Levels | Drug: Pioglitazone;Drug: Placebo | University of Michigan | National Institute on Alcohol Abuse and Alcoholism (NIAAA);Takeda Pharmaceuticals North America, Inc. | Not recruiting | 18 Years | 75 Years | All | 64 | Phase 2 | United States |
| 52 | NCT00755573 | October 2008 | 19 February 2015 | Pain and Chronic Pancreatitis - Clinical End Experimental Studies | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical and Experimental Pilot Study of Pregabalin in Patients With Chronic Pancreatitis | Chronic Pancreatitis | Drug: Pregabalin;Drug: placebo | Aalborg Universitetshospital | Radboud University | Not recruiting | 18 Years | 75 Years | Both | 64 | Phase 2/Phase 3 | Denmark;Netherlands |
| 53 | NCT00744250 | August 2008 | 19 February 2015 | Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control | Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control in Patients With Pancreatic Insufficiency | Exocrine Pancreatic Insufficiency;Chronic Pancreatitis;Cystic Fibrosis | Drug: Pancrelipase | Digestive Care, Inc. | University of North Carolina, Chapel Hill | Not recruiting | 18 Years | N/A | Both | 3 | Phase 4 | United States |
| 54 | EUCTR2008-002671-27-DK | 14/07/2008 | 17 October 2016 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP CLINICAL AND EXPERIMENTAL PILOTSTUDY OF PREGABALIN IN PATIENTS WITH CHRONIC PANCREATITIS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP CLINICAL AND EXPERIMENTAL PILOTSTUDY OF PREGABALIN IN PATIENTS WITH CHRONIC PANCREATITIS | Chronic pancreatitis MedDRA version: 9.1 Level: LLT Classification code 10033649 Term: Pancreatitis chronic | Trade Name: Lyrica Pharmaceutical Form: Capsule, hard INN or Proposed INN: pregabalin CAS Number: 148553508 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- INN or Proposed INN: Pregabalin CAS Number: 148553508 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Department of Medical Gastroenterology | Not Recruiting | Female: yes Male: yes | 45 | Phase 3 | Denmark | |||
| 55 | NCT00401076 | July 2008 | 19 February 2015 | A Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Pancreatic Exocrine Insufficiency | A One-year Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Patients With Pancreatic Exocrine Insufficiency Caused by Chronic Pancreatitis or by Pancreatectomy | Pancreatic Exocrine Insufficiency, Chronic Pancreatitis, Pancreatectomy | Drug: SA-001 | Abbott | Not recruiting | 20 Years | N/A | Both | 80 | Phase 3 | Japan | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 56 | NCT00705978 | June 2008 | 19 February 2015 | Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis | A One Week Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study With Creon 40,000 MMS in Subjects With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis, Followed by an Open-Label Long-Term Extension | Pancreatic Insufficiency | Drug: Pancreatin;Drug: Placebo | Abbott Products | Quintiles, Datamap | Not recruiting | 18 Years | N/A | Both | 62 | Phase 3 | India |
| 57 | EUCTR2008-000061-37-IT | 02/04/2008 | 19 March 2012 | A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of two doses of Zentase? (EUR-1008) in Chronic Pancreatitis (CP) patients with Exocrine Pancreatic Insufficiency (EPI) - PR-002 | A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of two doses of Zentase? (EUR-1008) in Chronic Pancreatitis (CP) patients with Exocrine Pancreatic Insufficiency (EPI) - PR-002 | Chronic Pancreatitis (CP) with Exocrine Pancreatic Insufficiency (EPI) MedDRA version: 9.1 Level: SOC Classification code 10017947 Term: Gastrointestinal disorders | Product Name: ZENTASE Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: Multienzymes (lipase, protease etc.) Concentration unit: U unit(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Gastro-resistant capsule, hard Route of administration of the placebo: Oral use | EURAND SPA | Not Recruiting | Female: yes Male: yes | 72 | Italy | ||||
| 58 | NCT00559052 | March 2008 | 19 February 2015 | An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI) | An Open-Label Cross-over Study to Evaluate the Intraduodenal Delivery of Lipase, Protease and Amylase From Administration of VIOKASE16 in Chronic Pancreatitis Subjects With Exocrine Pancreatic Insufficiency (EPI). | Exocrine Pancreatic Insufficiency | Drug: VIOKASE 16 | Axcan Pharma | AAIPharma;Mayo Clinical Services;City Hospital Laboratory Birmingham | Not recruiting | 18 Years | N/A | Both | 22 | Phase 2 | United States;Czech Republic |
| 59 | NCT00658736 | March 2008 | 16 December 2017 | Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis | A Randomized, Triple-Blinded Study of Endoscopic Ultrasound Guided Celiac Plexus Blockade (EUS-CPB) With Bupivicaine and Triamcinolone vs. Bupivicaine Alone for the Treatment of Pain in Chronic Pancreatitis | Chronic Pancreatitis | Drug: Triamcinolone;Drug: Bupivicaine alone | The Cleveland Clinic | American Society for Gastrointestinal Endoscopy;TAP Pharmaceutical Products Inc. | Not recruiting | 18 Years | N/A | All | 40 | Phase 3 | United States |
| 60 | EUCTR2007-004004-12-BG | 28/02/2008 | 19 March 2012 | A STUDY TO INVESTIGATE THE EFFECT OF PANCRELIPASE DELAYED RELEASE CAPSULES ON MALDIGESTION IN PATIENTS WITH EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY | A STUDY TO INVESTIGATE THE EFFECT OF PANCRELIPASE DELAYED RELEASE CAPSULES ON MALDIGESTION IN PATIENTS WITH EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY | Pancreatic enzyme replacement therapy is the cornerstone of nutritional management of pancreatic exocrine insufficiency (PEI) due to e.g. cystic fibrosis, chronic pancreatitis, partial or complete pancreatectomy or gastrectomy. Without pancreatic enzyme replacement the patients suffer from severe symptoms of maldigestion as manifested by steatorrhea, abdominal pain, body weight loss etc. MedDRA version: 9.1 Level: LLT Classification code 10009093 Term: Chronic pancreatitis MedDRA version: 9.1 Level: LLT Classification code 10033596 Term: Pancreatectomy | Trade Name: Creon 10000 Product Name: Pancrelipase Delayed Release Capsule Pharmaceutical Form: Capsule, hard Other descriptive name: Pancrelipase/Pancreas Powder Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 12000- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Creon 25000 Product Name: Pancrelipase Delayed Release Capsule Pharmaceutical Form: Capsule, hard Other descriptive name: Pancrelipase/Pancreas Powder Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 24000- | Solvay Pharmaceuticals GmbH | Not Recruiting | Female: yes Male: yes | 52 | Bulgaria | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 61 | EUCTR2007-000375-42-DK | 21/02/2008 | 19 March 2012 | A multi-center, double-blind, parallel-design, randomized, placebo-controlled, dose-ranging study to assess the efficacy and safety of oral recombinant microbial lipase (SLV339) in subjects with pancreatic exocrine insufficiency due to chronic pancreatitis | A multi-center, double-blind, parallel-design, randomized, placebo-controlled, dose-ranging study to assess the efficacy and safety of oral recombinant microbial lipase (SLV339) in subjects with pancreatic exocrine insufficiency due to chronic pancreatitis | Pancreatic exocrine insufficiency due to chronic pancreatitis MedDRA version: 9.1 Level: LLT Classification code 10009093 Term: Chronic pancreatitis | Product Name: Recombinant microbial lipase Product Code: SLV339 Pharmaceutical Form: Capsule, hard Current Sponsor code: SLV339 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Solvay Pharmaceuticals GmbH | Not Recruiting | Female: yes Male: yes | 80 | Hungary;Czech Republic;Denmark;Latvia;Sweden | ||||
| 62 | NCT00620919 | February 2008 | 19 February 2015 | Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis | RG1068 (Synthetic Human Secretin) Enhanced Multidetector CT Pancreatography: Evaluation of the Pancreatic Duct in Patients With Known or Suspected Chronic Pancreatitis | Chronic Pancreatitis | Drug: RG1068 (Synthetic Human Secretin) | Massachusetts General Hospital | Not recruiting | 18 Years | 90 Years | Both | 0 | Phase 1 | United States | |
| 63 | NCT00621283 | February 2008 | 19 February 2015 | Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population | RG1068 (Synthetic Human Secretin) Enhanced MRCP for Morphological Evaluation of the Pancreatic Duct in the Pediatric Population | Acute Recurrent Pancreatitis;Chronic Pancreatitis | Drug: RG1068 (Synthetic Human Secretin) | Massachusetts General Hospital | Not recruiting | 2 Years | 18 Years | Both | 0 | Phase 1 | United States | |
| 64 | NCT00788593 | January 2008 | 19 October 2017 | A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI) | A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 in Chronic Pancreatitis (CP) Patients With Exocrine Pancreatic Insufficiency (EPI) | Chronic Pancreatitis;Exocrine Pancreatic Insufficiency | Drug: Placebo;Drug: EUR-1008 (APT-1008) High Dose;Drug: EUR-1008 (APT-1008) Low Dose | Forest Laboratories | Not recruiting | 18 Years | N/A | All | 82 | Phase 3 | United States;Italy;Ukraine | |
| 65 | NCT00500084 | December 2007 | 19 February 2015 | Phase III ALTU-135 CP Safety Trial | An Open-Label Clinical Study Evaluating the Long Term Safety of ALTU-135 in the Treatment of Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis or Pancreatectomy | Exocrine Pancreatic Insufficiency | Drug: Liprotamase | Anthera Pharmaceuticals | Not recruiting | 18 Years | N/A | Both | 39 | Phase 3 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 66 | NCT00559364 | November 2007 | 16 December 2017 | Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea | A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled, Phase III Study to Assess the Safety and Efficacy of Viokase® 16 for the Correction of Steatorrhea in Patients With Exocrine Pancreatic Insufficiency | Exocrine Pancreatic Insufficiency;Chronic Pancreatitis;Pancreatectomy | Drug: Viokase® 16;Drug: Placebo;Drug: Proton pump inhibitor (PPI);Drug: Omeprazole | Forest Laboratories | Not recruiting | 18 Years | 80 Years | All | 50 | Phase 3 | United States;Canada;Poland;Slovakia;Germany | |
| 67 | NCT00414908 | October 2007 | 19 October 2017 | A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy | A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy | Chronic Pancreatitis;Pancreatectomy;Pancreatic Exocrine Insufficiency | Drug: Pancrelipase delayed release capsule;Drug: Placebo Comparator | Solvay Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 52 | Phase 3 | United States;Bulgaria;Poland;Puerto Rico;Russian Federation;Serbia;South Africa;Ukraine;Former Serbia and Montenegro | |
| 68 | EUCTR2006-006958-10-GB | 26/09/2007 | 19 March 2012 | Anticipate Trial - Randomized, Double blind, placebo-controlled, multicentre Trial of Anti-oxidant therapy in painful chronic pancreatitis. - Aniticipate trial | Anticipate Trial - Randomized, Double blind, placebo-controlled, multicentre Trial of Anti-oxidant therapy in painful chronic pancreatitis. - Aniticipate trial | Chronic Pancreatitis | Product Name: Antox version 1.2 Pharmaceutical Form: Coated tablet Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use | Pharmanord, UK, LTD | Authorised | Female: yes Male: yes | 60 | United Kingdom | ||||
| 69 | NCT00400842 | May 2007 | 19 February 2015 | A Study of SA-001 to Treat Pancreatic Exocrine Insufficiency | A Double-blind, Placebo-controlled, Parallel-group, Comparative Study to Confirm the Safety and Efficacy of Oral 1.5 g/Day and 3.0 g/Day of SA-001 in Patients With Pancreatic Exocrine Insufficiency Caused by Chronic Pancreatitis or by Pancreatectomy | Exocrine Pancreatic Insufficiency, Chronic Pancreatitis | Drug: SA-001;Drug: Placebo | Abbott | Not recruiting | 20 Years | N/A | Both | 274 | Phase 3 | Japan | |
| 70 | NCT00588367 | April 2006 | 28 April 2015 | CT Pancreas Perfusion | CT Perfusion of Pancreatic Cancer and Chronic Pancreatitis: Feasibility Study | Pancreatic Ductal Adenocarcinoma;Chronic Pancreatitis;Autoimmune Pancreatitis | Device: Mayo Interactive Breath Hold Monitor | Mayo Clinic | Not recruiting | 18 Years | N/A | Both | 30 | N/A | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 71 | NCT00156403 | August 2005 | 19 February 2015 | A Pilot Study of Use of Calcium Channel Blocker to Decrease Inflammation and Pain in Hereditary Pancreatitis | Hereditary Pancreatitis Amlodipine Trial(H-PAT): A Pilot Study | Pancreatitis | Drug: amlodipine (drug) | University of Pittsburgh | National Center for Research Resources (NCRR) | Not recruiting | 6 Years | N/A | Both | 8 | Phase 1/Phase 2 | United States |
| 72 | NCT00469703 | August 2005 | 19 February 2015 | Safety and Efficacy Study of Thalomid in Patients With Chronic Pancreatitis | A Phase II, Open-Label, Single Center Pilot Study to Determine the Safety and Efficacy of THALOMID (Thalidomide) in Patients With Chronic Pancreatitis. | Chronic Pancreatitis | Drug: Thalidomide | Winthrop University Hospital | Celgene Corporation | Not recruiting | 18 Years | 75 Years | Both | 10 | Phase 2 | United States |
| 73 | EUCTR2005-000736-24-DE | 14/07/2005 | 10 February 2014 | RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AN ENTERIC-COATED PANCREATIN TABLET FOR LIPID DIGESTION AND ABSORPTION IN PATIENTS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CHRONIC PANCREATITIS BY MEANS OF 13C-MIXED TRIGLYCERIDE BREATH TEST - CPI 003 | RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AN ENTERIC-COATED PANCREATIN TABLET FOR LIPID DIGESTION AND ABSORPTION IN PATIENTS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CHRONIC PANCREATITIS BY MEANS OF 13C-MIXED TRIGLYCERIDE BREATH TEST - CPI 003 | The purpose of this trial is to evaluate the clinical efficacy and safety of an enteric-coated pancreatin tablet in comparison to placebo in the treatment of pancreatic exocrine insufficiency due to chronic pancreatitis. MedDRA version: 7.0 Level: LLT Classification code 10033628 | Trade Name: Helopanflat Mono® Product Name: Helopanflat Mono® Product Code: Pancreatin Pharmaceutical Form: Gastro-resistant tablet INN or Proposed INN: Pancreatin Concentration unit: IU international unit(s) Concentration type: not less then Concentration number: 10000 IU-lipase Pharmaceutical form of the placebo: Gastro-resistant tablet Route of administration of the placebo: Oral use | Berlin-Chemie AG | Not Recruiting | Female: yes Male: yes | 20 | Phase 4 | Germany | |||
| 74 | NCT00142233 | June 6, 2005 | 26 November 2018 | EUROPAC-2 - Pain Treatment of Hereditary and Idiopathic Pancreatitis | Double Blind Randomised Controlled Trial to Investigate the Efficacy of ANTOX (Vers) 1.2 and MGCT (Magnesiocard) for the Treatment of Hereditary Pancreatitis and Idiopathic Chronic Pancreatitis | Pancreatitis | Dietary Supplement: ANTOX (vers.)1.2;Drug: Magnesium;Other: Placebo ANTOX (vers)1.2;Other: Placebo Magnesiocard (2.5 mmol) | University Medicine Greifswald | Not recruiting | 5 Years | 75 Years | All | 295 | Phase 3 | Germany | |
| 75 | NCT01154608 | April 2005 | 19 February 2015 | Effect of Enzyme Therapy on Protein Metabolism in Chronic Pancreatitis | Pancreatitis | Drug: Creon;Other: No enzyme therapy | Institut National de la Recherche Agronomique | National Research Agency, France;Solvay Pharmaceuticals | Not recruiting | 18 Years | N/A | Both | 11 | N/A | France | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 76 | EUCTR2004-002468-89-DE | 28/10/2004 | 19 March 2012 | A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PANCREATIN VS. PLACEBO FOR LIPID DIGESTION AND ABSORPTION IN PATIENTS WITH PANCREATIC EXOCRINE INSUFFICIENCY - Pancreatin vs. Placebo in Patients with Pancreatic Exocrine Insufficiency | A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PANCREATIN VS. PLACEBO FOR LIPID DIGESTION AND ABSORPTION IN PATIENTS WITH PANCREATIC EXOCRINE INSUFFICIENCY - Pancreatin vs. Placebo in Patients with Pancreatic Exocrine Insufficiency | The purpose of this clinical trial is to evaluate the clinical efficacy and safety of a capsule containing enteric-coated porcine pancreatin microfilm tablets in comparison with placebo in the treatment of pancreatic exocrine insufficiency due to chronic pancreatitis. MedDRA version: 7.0 Level: LLT Classification code 10033622 | Trade Name: Panzytrat 25.000 Product Name: Panzytrat 25.000 Product Code: Pancreatin Pharmaceutical Form: Capsule* INN or Proposed INN: Pancreatin Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 25.000-IU lipase Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | Axcan Pharma S.A. | Not Recruiting | Female: yes Male: yes | 20 | Phase 4 | Germany | |||
| 77 | NCT00957151 | April 2004 | 19 February 2015 | Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis | Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis | Chronic Pancreatitis | Drug: Creon | Hospital Avicenne | Solvay Pharmaceuticals | Not recruiting | 18 Years | 65 Years | Both | 12 | Phase 4 | France |
| 78 | NCT00319358 | October 2003 | 19 February 2015 | Role of Antioxidants Supplementation in Chronic Pancreatitis | Effect of Antioxidant Supplementation on Pain, Antioxidant Profile and Oxidative Stress in Patients With Chronic Pancreatitis | Chronic Pancreatitis | Dietary Supplement: Antioxidants;Dietary Supplement: Placebo | All India Institute of Medical Sciences, New Delhi | Not recruiting | 12 Years | 70 Years | Both | 127 | Phase 3 | India | |
| 79 | NCT00583271 | June 2002 | 19 February 2015 | A Prospective Study of EUS Guided Celiac Block | A Prospective Study of Endoscopic Ultrasound-guided Celiac (CB) Effectiveness | Chronic Pancreatitis;Pancreatic Cancer | Drug: triamcinolone;Drug: 98% dehydrated alcohol | Indiana University | Not recruiting | 18 Years | N/A | Both | 127 | N/A | United States |